Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …

Oncolytic viruses (OVs) have attracted growing awareness in the twenty-first century, as they
are generally considered to have direct oncolysis and cancer immune effects. With the …

In this review, we discuss the use of oncolytic viruses in cancer immunotherapy treatments in
general, with a particular focus on adenoviruses. These serve as a model to elucidate how …

In the wake of the success of modern immunotherapy, oncolytic viruses (OVs) are currently
seen as a potential therapeutic option for patients with cancer who do not respond or fail to …

To effectively build on the recent successes of immune checkpoint blockade, adoptive T cell
therapy and cancer vaccines, it is critical to rationally design combination strategies that will …

Oncolytic viral therapy is a new promising strategy against cancer. Oncolytic viruses (OVs)
can replicate in cancer cells but not in normal cells, leading to lysis of the tumor mass …

Antibodies (Abs) containing two different antigen-binding sites in one molecule are called
bispecific. Bispecific Abs (BsAbs) were first described in the 1960s, the first monoclonal …

The recent successes of tumor immunotherapy approaches, such as immune checkpoint
blockade (ICB) and chimeric antigen receptor T cell (CAR-T) therapy, have revolutionized …

The redirection of T cells against tumors holds much promise for the treatment of cancer.
Two main approaches for T-cell redirection involve their genetic modification with chimeric …

Bispecific antibodies (bsAbs) refer to a large family of molecules that recognize two different
epitopes or antigens. Although a series of challenges, especially immunogenicity and chain …